Of Counsel

Email: sradkov@dbllawyers.com

Office: London UK

  • As an undergraduate, Dr. Radkov studied Microbiology graduating with the highest 1st Class BSc Honours degree in the Faculty of Animal & Microbial Sciences, University of Reading – awarded The Abbott Laboratories Prize. PhD in Viral Oncology – The Ludwig Institute for Cancer Research, St Mary’s Hospital – Imperial College London and a Cancer Research Campaign (CRC) funded Senior Research Fellow at Imperial College London and University College London – scientific findings published in Virology and Nature Medicine as detailed below.
  • After a successful career as a scientist, Dr. Radkov joined a top tier Intellectual Property Law firm, D Young & Co in London, where he trained as a Life Sciences Patent Attorney. Attained, a Post Graduate Diploma in Intellectual Property Law from Queen Mary & Westfield, University of London & fully qualified as European Patent Attorney (EPA) – chemistry.
  • Dr. Radkov has over 18 years of experience in international and European IP law, serving as a Global Product Attorney at Pfizer in Sandwich, England; Novartis and Syngenta Headquarters in Basel, Switzerland:
  • Pfizer – Provided patent support to the anti-viral and anti-invectives research & diagnostics teams – HCV (RNAi & Ab based therapies), HIV and Salmonella. Extensive experience in patent strategy for early and late stage research & diagnostic portfolios. IP Due Diligence (M&A, licensing opportunities etc.), FTO, Validity, Patentability & Infringement Opinions. International Licence negotiations and strategic advice;
  • Novartis – Global Product Attorney for Galvus, Eucreas and Canakinumab. I was responsible for Due Diligence, FTO, Validity, Patentability & Infringement Opinions and work-around strategies. Patent drafting with EP & global patent prosecution.
  • Syngenta – Biotech EP Patent Team Lead and Global RNAi Team Lead. Providing strategic advice relating to direction of RNAi research, licensing and M&A opportunities. Responsible attorney for the M&A IP assessments as part of a global DD process for the acquisition of Devgen (value of completed deal €403million).
  • Recommended in Legal 500 New partner Dr Stoyan Radkov specializes in high-value oppositions and appeals at the EPO, representing clients from the biotech and life sciences industries” – 2015.
  • 2000 – Nature Medicine: The Latent Nuclear Antigen of Kaposi-Sarcoma associated herpes virus targets the retinoblastoma-E2F pathway and with the oncogene H-ras transforms primary rat cells. http://www.nature.com/nm/journal/v6/n10/full/nm1000_1121.html?foxtrotcallback=true
  • 1999 – Journal of Virology: Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. http://jvi.asm.org/cgi/content/ abstract/73/7/5688
  • 1997 – Journal of Virology: Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. http://jvi.asm.org/cgi/content/abstract/71/11/8552.
  • 1995 – ABBOTT LABORATORIES PRIZE for the highest degree in School of Animal and Microbial Sciences, University of Reading.
  • 1994 – ABBOTT LABORATORIES PRIZE for academic excellence.